DiscoverFacts MatterFDA Suspends Ixchiq Vaccine After 1.5 Years of Safety Data Showed Serious Risk
FDA Suspends Ixchiq Vaccine After 1.5 Years of Safety Data Showed Serious Risk

FDA Suspends Ixchiq Vaccine After 1.5 Years of Safety Data Showed Serious Risk

Update: 2025-08-27
Share

Description

On Aug. 25, the FDA informed the public that the agency officially suspended its approval for Valneva’s Ixchiq vaccine.

Ixchiq is a vaccine for Chikungunya, a mosquito-borne disease. The vaccine was initially approved to be administered in the United States in November 2023, under the FDA’s fast-tracked accelerated approval pathway.


Let’s go through what the data showed, as well as why the FDA decided this move to stop the vaccine was necessary.

Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

FDA Suspends Ixchiq Vaccine After 1.5 Years of Safety Data Showed Serious Risk

FDA Suspends Ixchiq Vaccine After 1.5 Years of Safety Data Showed Serious Risk